Uma Thurman
Showing 1–1 of 1 transcripts.
- Milken Institute49 min
Can Psychedelics Improve Mental Health? With C. Angermayer & Uma Thurman | Global Conference 2021
C. Angermayer, Uma Thurman, Christian Angermayer, Robert Mancini
German biotech investor Christian Angermeyer founded Atai Life Sciences to develop psychedelic therapeutics capable of treating over one billion people suffering from mental health conditions that current standard medications often fail to address. By targeting the brain's Default Mode Network to induce neuroplasticity, Angermeyer's pipeline includes non-addictive compounds like psilocybin and MDMA intended to be administered under strict medical supervision rather than for recreational use. The strategic goal is to reclassify these substances through rigorous FDA protocols to resolve widespread anxiety, addiction, and trauma while eventually fostering broader societal reconciliation as medical efficacy becomes undeniable.